Beyond Insulin: Why Type 1 Diabetes Mellitus Needs More?

Area of Science:

• Endocrinology and Metabolism
• Cardiovascular Disease Research
• Diabetes Mellitus Type 1

Background:

• Despite insulin's discovery 100 years ago, type 1 diabetes (T1D) patients still face significant cardiovascular risk and mortality.
• Traditional risk factors and dysglycemia alone do not fully account for the elevated cardiovascular burden in T1D.
• Emerging evidence points to glycemic variability, insulin-induced weight gain, insulin resistance, and hormonal imbalances as key contributors.

Purpose of the Study:

• To explore the complex mechanisms underlying elevated cardiovascular risk in type 1 diabetes.
• To review current therapeutic agents targeting these non-glycemic pathways.
• To identify gaps in knowledge regarding long-term cardiovascular outcomes.

Main Methods:

• Literature review and synthesis of current research on T1D pathophysiology and cardiovascular complications.
• Analysis of existing therapeutic strategies and their impact on identified risk mechanisms.
• Critical evaluation of available data on hard cardiovascular endpoints in T1D.

Main Results:

• Glycemic variability, weight gain, insulin resistance, and hormonal disturbances significantly contribute to cardiovascular risk in T1D.
• Several classes of agents targeting these pathways are available, but their long-term efficacy requires further investigation.
• Data on hard cardiovascular endpoints and long-term outcomes in T1D patients using these novel approaches remain limited.

Conclusions:

• Addressing multifaceted cardiovascular risk factors beyond glycemic control is crucial for improving outcomes in T1D.
• Further research is needed to evaluate the long-term cardiovascular benefits of emerging therapeutic agents.
• Clinical trials focusing on hard cardiovascular endpoints are essential for guiding future treatment strategies in T1D.